PharmaShots | Incisive News in 3 Shots

Subscribe Now

No

F2G's Olorofim Receives the US FDA's Breakthrough Therapy Designation to Treat Invasive Mold Infections in Patients with Limited or No Treatment Options

F2G's Olorofim Receives the US FDA's Breakthrough Therapy Designation to Treat Invasive Mold Infections in Patients with Limited o...

November 11, 2019

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Type-2 Diabetes (T2D)

AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Trial for Patients with Coronary Artery Disease (CAD) and Typ...

February 25, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us